{
    "code": 0,
    "data": [
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "c47f09c6-37eb-4803-a45b-894c06d2e701",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=58387b0d-b3f2-43fd-9542-6c89585316cd.pdf",
            "news_date": "2026-02-12 17:32:54",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of Board Meeting",
            "news_body": "Outcome of Board Meeting",
            "news_id": "82440700-c879-4b95-ba93-c39c84fb89cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0397614a-7158-46d8-b89a-ba9953de9bbe.pdf",
            "news_date": "2026-02-12 17:20:46",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "daa7749b-3ddd-4a36-9c47-ee30f84ab08e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c6d703a0-9c33-483f-aad5-2a83e1acbde8.pdf",
            "news_date": "2025-11-12 18:56:47",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Meeting",
            "news_body": "Outcome of the meeting",
            "news_id": "fa08c078-cd50-4f3d-8b4a-c3b5f37466fe",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f2980fa-adb3-449f-9e81-839ea46ed7b1.pdf",
            "news_date": "2025-11-12 18:37:16",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript",
            "news_id": "2aa74387-3d8f-4306-9e63-0ebcc5720573",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a5bb5a8f-229c-40b8-b3cb-c40f09a91bdb.pdf",
            "news_date": "2025-08-19 17:01:32",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "8fb6b20d-5fb8-4fae-98a1-7771332aa155",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=536f1fc9-8042-4b24-9b24-c52e2c8af247.pdf",
            "news_date": "2025-08-13 17:14:28",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript",
            "news_id": "c59c6678-5c68-46cc-a6cf-4bd6978e0235",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12e3bc92-c179-4924-b331-cd06f046178a.pdf",
            "news_date": "2025-06-02 15:11:34",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Period Ended March 31 2025",
            "news_body": "Financial Results for period ended March 31 2025",
            "news_id": "cc6cc525-0e60-4aa1-bb5e-64a3b6e36d4a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2455072f-609c-4850-a5c8-8f989d13f9c7.pdf",
            "news_date": "2025-05-28 18:49:08",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "bad3fd19-a9cc-4355-9e46-f2f5cb936402",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a15a7709-e546-47ca-9d16-727c2e444ba2.pdf",
            "news_date": "2025-05-28 17:55:19",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings call Transcript",
            "news_id": "88befc7d-c94c-4929-97e1-ece1ae00e5a6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=654a8886-30e6-4ce7-be5d-dba4ae41cad4.pdf",
            "news_date": "2025-02-18 12:59:26",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "ff37972b-188e-4bbe-bb5f-9d7aef8848fb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb4be0eb-03d9-4792-a416-2d841ccee064.pdf",
            "news_date": "2025-02-12 17:46:25",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "0e61bb7c-289f-460b-a4f0-bdf4a56c9070",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b8256e9-3113-47df-be4b-acefc441005e.pdf",
            "news_date": "2025-01-15 09:53:54",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "9f992a64-a907-4de0-a22f-40d5964cfea4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=433e8bee-aee8-4d2c-9c9a-df70fb1973d5.pdf",
            "news_date": "2024-12-07 08:02:25",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Earnings Call Transcript",
            "news_id": "f721a5d9-05a3-493e-87f2-b0e237094890",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b2bd328a-a01c-4ee6-a211-eeed80578b93.pdf",
            "news_date": "2024-11-17 19:44:56",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "cfc3a4da-a1d6-45ee-a3a7-86d9c8be796b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fa99890-a8ba-40ca-a67e-43efc369781a.pdf",
            "news_date": "2024-11-12 18:43:58",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings conference call for the quarter ended  June 30, 2024",
            "news_id": "d958608f-7189-44b6-be23-bbd545865b0b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82d83640-8d3c-485c-9e89-96dd51775921.pdf",
            "news_date": "2024-08-14 15:41:13",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "13ee36cd-4a07-4c73-9520-5873b04c80f8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3705277e-aa34-44fa-b02e-5ecf56efe36e.pdf",
            "news_date": "2024-08-09 15:34:46",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated June 13, 2024, the audio recording of the conference call for acquisition of a majority stake in Sapala Organics held on Wednesday, June 19, 2024, has beenuploaded on the Company''s website",
            "news_id": "c792a547-47bb-41d7-807b-5347228b3ba4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=10e462a2-76e8-4280-a5f2-0ea9d1b0de0a.pdf",
            "news_date": "2024-06-19 18:56:13",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "28b97166-659b-4b05-87f9-bb1f34daab00",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=339e9a96-294c-4343-92e9-8735f02b4a1f.pdf",
            "news_date": "2024-06-13 17:31:42",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings conference call for the quarter and year ended March 31, 2024 conducted on May 30, 2024",
            "news_id": "825cbc30-47ea-469c-8a28-a37d3ddcb7eb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2ac51a1f-5a6d-4b83-9800-30cd495dd609.pdf",
            "news_date": "2024-06-04 18:09:57",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of the earnings conference call for the quarter and year ended March 31, 2024",
            "news_id": "c87656ab-37fc-4f53-b4fd-3827f737b693",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e2d551be-2c47-44d0-a0e9-a1940bbca4c5.pdf",
            "news_date": "2024-05-31 14:30:56",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "d127f48a-ab29-4f06-a25c-e559097600ec",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4ff798d8-b0a0-4de6-bce6-b8aaf62e921b.pdf",
            "news_date": "2024-05-30 17:39:09",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "Outcome of the Board Meeting",
            "news_id": "34908bad-36ee-4de8-bd34-7229de5987df",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bf4a23b1-90d5-4012-ba81-1f7235c6d0b4.pdf",
            "news_date": "2024-05-30 17:38:07",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to the proposed merger and the business outlook conference call intimation dated February 29, 2024, the audio recording of the conference call held on Tuesday, March 05, 2024.",
            "news_id": "8799c038-c1b2-4519-ad61-14c3f1a0a64f",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=12ae0710-6bc9-4432-8117-327fc02011f1.pdf",
            "news_date": "2024-03-06 12:52:50",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "67c1d5b6-e2ed-4349-9a1f-528a8ed36158",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=197c3ef9-292f-409f-a9ca-312f1c8b0e05.pdf",
            "news_date": "2024-02-29 19:12:24",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings conference call for the quarter and nine months ended December 31, 2023",
            "news_id": "65084540-cb2f-473d-8ffb-e3495a18e0e4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bbf41c15-a395-4b00-99f1-32920e195521.pdf",
            "news_date": "2024-02-09 14:02:07",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Audio recording of the earnings conference call for the quarter and nine months ended December 31, 2023",
            "news_id": "b57f5508-b22f-4af4-95df-46f552178ee5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a399109-a325-49a8-8705-7c08e6316b84.pdf",
            "news_date": "2024-02-06 11:17:27",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation",
            "news_id": "0775570b-d32e-45d8-ab7d-0cc5cbb1cdc2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c83dda9b-803d-4f4e-89ba-86b4bee6c331.pdf",
            "news_date": "2024-02-05 17:26:32",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "unaudited standalone and consolidated financial results for quarter and nine months ended December 31, 2023 , Limited Review Reports, Press Release and Investors Presentation.",
            "news_id": "a2c1b717-70c4-4dab-996f-3d8612c78c3b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=094c1d73-6e66-4ded-b61f-a62b37f753c2.pdf",
            "news_date": "2024-02-05 17:19:50",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Updated Investor Presentation_Q2 FY 2024",
            "news_id": "a6db242c-8023-42e1-967f-bf857f0e504b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d32da58-075b-49ae-8a5f-3c8ba480a8b8.pdf",
            "news_date": "2023-11-24 17:13:02",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Transcript of the earnings conference call for the quarter and half year ended September 30, 2023",
            "news_id": "69ee3d24-2643-4f08-a395-e00e58308488",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d400973-cd22-48bb-8500-90c6e2c829b9.pdf",
            "news_date": "2023-11-14 17:04:16",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated November 02, 2023, that audio recording of the conference call for the quarter and half year ended September 30, 2023 held on Thursday, November 09, 2023, has been uploaded on the Company''s website at https://suvenpharm.com/financial-info/",
            "news_id": "30ff221d-29ce-4a6b-9f0b-9cfa3fecaf84",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=feb869a0-60d6-4b99-b90e-869db4b066e1.pdf",
            "news_date": "2023-11-10 12:08:13",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find enclosed investor presentation",
            "news_id": "f369ea7b-ae6b-44f8-8f25-1c88380650f0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cefee64d-9d8c-407b-a3c7-2c12b646f070.pdf",
            "news_date": "2023-11-09 18:08:03",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results Prepared Under Ind AS For The Quarter And Half Year Ended September 30, 2023",
            "news_body": "Un- Audited Standalone and consolidated FInancial Results prepared under INA AS for quarter and half year ended September 30, 2023",
            "news_id": "980a69aa-6e1e-405a-b206-631edbfbbaa3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca29f15c-7058-403d-a1f4-8a58033be1bc.pdf",
            "news_date": "2023-11-09 17:49:08",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Please find enclosed the transcript of the earnings conference call for the quarter ended Juen 30, 2023.",
            "news_id": "54160177-2f78-48b1-9abc-e12a61404547",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e69c1b94-23c3-4cde-b4bf-0a7d538291cc.pdf",
            "news_date": "2023-08-14 15:07:23",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated August 10, 2023, that audio recording of the conference call for the quarter ended June 30, 2023 held on Thursday, August 10, 2023, has been uploaded on the Company''s website at https://suvenpharm.com/financial-info/This is for your information and record.",
            "news_id": "78329ef9-c4e7-4396-a470-b8975e3059e5",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09f429c5-368f-4eab-b28e-735d5e7f1054.pdf",
            "news_date": "2023-08-11 14:11:10",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting-Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30Th June, 2023",
            "news_body": "we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. August 8, 2023, has taken on record and apporved the attached Un-audited Standalone and Conslidated Financial Results of the Company prepared under IND AS for the quarter ended 30th June, 2023 along with Limited Reveiw Reports of the Staturoty Auditors.",
            "news_id": "3bb70b46-26dc-4a10-8a18-5fe06da6249e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6713999-fab3-4a74-8248-81ea84c4c480.pdf",
            "news_date": "2023-08-08 16:14:25",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and year ended March 31, 2023 conducted after the meeting of Board of Directors held on May 25, 2023.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "2204e735-1f14-4d11-8b9f-b25f19eff898",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=396a77e6-9442-444b-919a-7898186a3439.pdf",
            "news_date": "2023-06-02 11:13:46",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to ourResults conference call intimation dated May 19, 2023, that audio recording of the conference call for the quarter and year ended March 31, 2023 held on Friday, May 26,2023, has been uploaded on the Company''s website athttps://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "19ba7f29-a009-4c98-997b-b6224af240eb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb33b498-b986-4884-a83b-f0e2bdeca36c.pdf",
            "news_date": "2023-05-26 20:06:17",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 25, 2023, has taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.<BR> <BR> Further, we are enclosing herewith the following documents:<BR> 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement.<BR> 2) Auditor's Reports on the financial results as mentioned above <BR> 3) Declaration in respect of Audit Reports with unmodified opinion and<BR> 4) Earnings Presentation of our company to investors",
            "news_id": "053d3413-02de-4932-9017-da1b95023d74",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=64445303-f53f-4b90-9b24-66a9ab8d3524.pdf",
            "news_date": "2023-05-25 13:41:20",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and nine months ended December 31, 2022 conducted after the meeting of Board of Directors held on February 6, 2023.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "cb8b0c4e-5b8d-49a8-9dde-af2697171c6e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af213eeb-7463-459f-bbbd-909061c1d705.pdf",
            "news_date": "2023-02-13 17:21:18",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated January 31, 2023, that audio recording of the conference call for the quarter and nine months ended December 31, 2022 held on Tuesday, February 7, 2023, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "957a7c24-4450-441b-86ba-db94236d81e8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b192d874-a0a1-4357-b119-f82115004ea2.pdf",
            "news_date": "2023-02-07 18:10:35",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December, 2022",
            "news_body": "With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. February 6, 2023, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and nine months ended 31st December, 2022.<BR> <BR> We are enclosing herewith the following documents:<BR> 1) Un-audited Standalone and Consolidated Financial Results for the quarter and nine months ended 31st December, 2022<BR> 2) Limited Review Reports on the financial results as mentioned above and<BR> 3) Earnings Presentation of our company to investors<BR> <BR> We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:55 P.M.<BR> <BR> This is for your information and record.",
            "news_id": "1978637b-ed76-4599-bd03-0f1725328f6a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c750c20f-3250-4b45-ba0d-1b77a8c4dc85.pdf",
            "news_date": "2023-02-06 13:12:32",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the conference call for the investors held on December 26, 2022.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-eventsThis is for your information and record.",
            "news_id": "c5596415-c524-4137-8dd7-f70ebf532226",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52f8c969-3d12-4560-b5aa-421709b894f3.pdf",
            "news_date": "2022-12-30 17:03:38",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated December 26, 2022, that audio recording of the conference call for the investors held on Monday, December 26, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events",
            "news_id": "c3ef9ae6-f9a7-4e81-8790-250a5c437d81",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5fcdc361-7f90-462c-9a2c-97c8732ade44.pdf",
            "news_date": "2022-12-27 14:17:05",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)",
            "news_body": "Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half-year ended 30th September, 2022.This is for your information and record.",
            "news_id": "dd8e371b-76f8-44ab-8c8b-b521b5b35325",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc8fb384-53d4-4df8-9e3d-912fc76b72e9.pdf",
            "news_date": "2022-11-21 19:20:25",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and half-year ended September 30, 2022 conducted after the meeting of Board of Directors held on November 8, 2022.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "3bf75a40-a490-4025-91dc-dcda5a08b8a8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbd6b3d9-58bc-4007-9c28-282cb8e6c77e.pdf",
            "news_date": "2022-11-15 14:31:36",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated November 3, 2022, that audio recording of the conference call for the quarter and half-year ended September 30, 2022 held on Wednesday, November 9, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "f93350a1-9536-43a7-9e95-b0c9c049a0c8",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e7a9022f-533c-4722-a9c0-83805b5d5b77.pdf",
            "news_date": "2022-11-10 15:00:44",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting-Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half-Year Ended 30Th September, 2022",
            "news_body": "With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2022.<BR> <BR> We are enclosing herewith the following documents:<BR> 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2022<BR> 2) Limited Review Reports on the financial results as mentioned above and<BR> 3) Earnings Presentation of our company to investors <BR> <BR> We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.<BR> <BR> This is for your information and record.",
            "news_id": "949f3579-be7e-4274-a6ea-f284a88ea77d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3572a033-578e-49ff-b98f-72445f474e60.pdf",
            "news_date": "2022-11-08 12:42:31",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter ended June 30, 2022 conducted after the meeting of Board of Directors held on August 8, 2022.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "b47ec2d5-962d-43ff-a859-5c735ed78c93",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c298072f-47d7-44a7-8562-8cdd714cd955.pdf",
            "news_date": "2022-08-16 11:36:35",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached Investor Presentation",
            "news_id": "7dbdef22-cf5f-4946-a32a-350bf0356488",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3fefb0ed-77d2-4549-8df3-2f7e62a7166c.pdf",
            "news_date": "2022-08-08 13:13:17",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. August 08, 2022, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter ended 30th June, 2022.<BR> <BR> We are enclosing herewith the following documents:<BR> 1) Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2022<BR> 2) Limited Review Reports on the financial results as mentioned above and<BR> 3) A copy of the News Release of our company <BR> <BR> We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:45 P.M.",
            "news_id": "dc1b0a4f-69c1-4cd0-a46d-d2019075af26",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ff821d63-888d-4428-b67d-1d9bb5d9fc25.pdf",
            "news_date": "2022-08-08 13:09:42",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para-A of Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the Analyst / Institutional Investor Meeting held on June 1, 2022.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-eventsThis is for your information and record.",
            "news_id": "5104b535-cf23-4f34-ada5-daacfe37dccc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1c9bd20-3e1f-4758-b655-0a140897b9a7.pdf",
            "news_date": "2022-06-08 12:17:48",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Analyst / Institutional Investor Meeting intimation dated May 31, 2022, that audio recording of the Analyst / Institutional Investor Meeting held on June 1, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-eventsThis is for your information and record.",
            "news_id": "3dcfb4f3-a443-4730-92bf-723fb38d0d24",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f385f491-e7e0-4308-a6fc-83aeb01b74c4.pdf",
            "news_date": "2022-06-02 18:09:33",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)",
            "news_body": "Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions and balances for the half-year ended 31st March, 2022.This is for your information and record.",
            "news_id": "8e8e921d-1c32-4117-85fb-a325c3ab04ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=33ca8804-6a10-4372-82b1-c971ed1e78a5.pdf",
            "news_date": "2022-05-21 16:55:53",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Earnings Call Transcript",
            "cat": "Transcript",
            "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and year ended March 31, 2022 conducted after the meeting of Board of Directors held on May 9, 2022.The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-releaseThis is for your information and record.",
            "news_id": "4e1dc26e-fcd9-434b-8828-70854bc9e9e3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe7fe75d-c717-494d-b8d2-fd9b8815dd9e.pdf",
            "news_date": "2022-05-13 15:27:56",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Analyst / Investor Meet",
            "cat": "Audio",
            "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
            "news_body": "Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated May 5, 2022, that audio recording of the conference call for the quarter and year ended March 31, 2022 held on Tuesday, May 10, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release",
            "news_id": "d0c3b81c-deab-4262-b643-fcf57cf907a7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ae8f6a1-151f-4c2a-b934-694515001acf.pdf",
            "news_date": "2022-05-11 12:39:09",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached Revised Investor Presentation for 4th Quarter and Annual - FY 2022",
            "news_id": "bf04976d-2d5a-49d2-9f27-6d76f944b8ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8d727e2-e904-439a-a67f-58606b928611.pdf",
            "news_date": "2022-05-09 16:44:16",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached investor presentation for 04th quarter and Annual - FY2022.",
            "news_id": "7457c418-542b-4c89-8b25-7a67b73dd997",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ccb78723-c4bd-4471-99a9-800c6e883c15.pdf",
            "news_date": "2022-05-09 14:32:45",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 9, 2022, approved the following along with other business matters.",
            "news_id": "065f8536-14c9-4276-927f-a2c19791afde",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7e6ffda1-2fc5-483b-b39b-db9395cb6cec.pdf",
            "news_date": "2022-05-09 13:09:21",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find attached Investor Presentation",
            "news_id": "c53e59ed-630e-4c50-b6a5-340d206cb24e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=63bbe343-4a6b-4a58-aded-9cbf4da5c2c6.pdf",
            "news_date": "2022-02-08 17:09:09",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended 31St December, 2021",
            "news_body": "With reference to the above subject, the Board of Directors of the company, at its meeting held today i.e. February 08, 2022, approved the following along with other business matters.",
            "news_id": "e0404454-9237-4401-a00c-a802998bf935",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=eb027470-c8e6-4853-8a66-f925c62d34d5.pdf",
            "news_date": "2022-02-08 13:14:57",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find enclosed Investor Presentation",
            "news_id": "bb24f918-f976-431b-956d-731e849be41a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6c2952a0-7512-4dab-b9d3-2ae2cbfd6d02.pdf",
            "news_date": "2021-11-06 21:46:54",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half-Year Ended 30Th September, 2021",
            "news_body": "With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. November 6, 2021, has taken on record and approved the Un-Audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter and half-year ended 30th September, 2021. Suven Pharmaceuticals Ltd .<BR> <BR> We are enclosing herewith the following documents:<BR> 1) Un-audited Standalone and Consolidated Financial Results for the quarter and half-year ended 30th September, 2021<BR> 2) Limited Review Reports on the financial results as mentioned above and<BR> 3) A copy of the News Release of our company<BR> <BR> We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:30 P.M.",
            "news_id": "5de91e14-296b-43ed-8175-5f09b54bee82",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c69e3dc-c861-43f4-8f38-39ce424ef61f.pdf",
            "news_date": "2021-11-06 12:52:14",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find enclosed Investor Presentation",
            "news_id": "5daefb67-395f-4595-b243-49fa05054b17",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a284c138-0e8e-4dd1-a24d-6985dc532a70.pdf",
            "news_date": "2021-08-16 09:47:04",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results Prepared Under Ind AS Along With Limited Review Reports Of The Statutory Auditors For The Quarter Ended 30Th June, 2021",
            "news_body": "With reference to the above subject, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the company, at its meeting held today i.e. August 13, 2021, has taken on record and approved the Un-audited Standalone and Consolidated Financial Results prepared under Ind AS along with Limited Review Reports of the Statutory Auditors for the quarter ended 30th June, 2021.<BR> <BR> We are enclosing herewith the following documents:<BR> 1) Un-audited Standalone and Consolidated Financial Results for the quarter ended 30th June, 2021<BR> 2) Limited Review Reports on the financial results as mentioned above and<BR> 3) A copy of the News Release of our company<BR> <BR> We request you to take these documents on your records. The Board Meeting commenced at 11:30 A.M. and concluded at 12:50 P.M.",
            "news_id": "822a6061-9257-4c22-92e1-517823553536",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=caeb99e6-562c-471e-878e-3d894796e3b8.pdf",
            "news_date": "2021-08-13 13:12:36",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations)",
            "news_body": "Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the year ended 31st March, 2021.",
            "news_id": "7221e978-e73f-4f79-991b-720df3bb89f9",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79f2032c-ad12-4ce7-9089-1dc0d8ad3058.pdf",
            "news_date": "2021-07-07 14:23:48",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Please find enclosed Investor Presentation Q4 and FY21",
            "news_id": "101ae18d-5b00-4ce8-a0d1-c5df64a98d18",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e3c8790c-35b2-423f-a3bd-93ae5df38f3b.pdf",
            "news_date": "2021-06-08 16:12:28",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "1. Financial Results<BR> <BR> Taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.<BR> <BR> 2. Dividend<BR> <BR> The Board recommended a final dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021.<BR> 3. e-Annual General Meeting and Record date<BR> (i). The 3rd e-Annual General Meeting of the members of the Company will be held on Tuesday, August 31, 2021 through VC/ OAVM.<BR> (ii). The Board approved the August 17, 2021 as record date for the purposes of the Annual General Meeting and final dividend. The final dividend will be paid on and from September 07, 2021, within 30 days from the date of approval by members in the AGM.",
            "news_id": "949affe5-ba12-4dc9-93b2-fef2130992df",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=555797c4-0bb3-4f26-965c-8fe70331b37c.pdf",
            "news_date": "2021-06-08 13:22:53",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "COHANCE",
            "disp": "Cohance Lifesciences",
            "bse_code": 543064,
            "isin": "INE03QK01018",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Outcome Of The Board Meeting",
            "news_body": "1. Financial Results<BR> Taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2021 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors.<BR> <BR> 2. Dividend<BR> The Board recommended a final dividend of Rs. 1.00 per equity share of face value of Rs 1/- each for the year 2020-2021.<BR> <BR> 3. e-Annual General Meeting and Record date<BR> (i). The 3rd e-Annual General Meeting of the members of the Company will be held on Tuesday, August 31, 2021 through VC/ OAVM.<BR> (ii). The Board approved the August 17, 2021 as record date for the purposes of the Annual General Meeting and final dividend. The final dividend will be paid on and from September 07, 2021, within 30 days from the date of approval by members in the AGM.<BR>",
            "news_id": "787327d6-e4cd-4955-b458-69ee3aaaf3e0",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b0e04631-22cb-44e9-a2cd-c038748b6612.pdf",
            "news_date": "2021-06-08 13:18:29",
            "seo": "suven-pharmaceuticals-ltd",
            "ltp": 355.25,
            "ch": 1.6999999999999886,
            "pch": 0.48083722245792354,
            "inst": "EQUITY",
            "ts": 0.05,
            "ls": 1,
            "mtp": 1,
            "sid": 17945,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}